Korro Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $156.98M
- P/E (TTM)
- –
- Dividend yield
- –
About Korro Bio
Pharmaceutical Preparations, SIC 2834
Korro Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes genetic medicines utilizing RNA editing technology to treat rare and highly prevalent human illnesses. The company employs its proprietary OPERA platform alongside oligonucleotides to harness the natural adenosine deaminase acting on RNA enzyme, creating transient single-nucleoside edits rather than permanent alterations to DNA. Its wholly-owned preclinical development pipeline includes KRRO-121 for hyperammonemia, an oligonucleotide program for alpha-1 antitrypsin deficiency, an AMPK gamma 1 activation program for liver health, and a therapy targeting TDP-43 for amyotrophic lateral sclerosis. The company designs its therapies for patient populations affected by metabolic, genetic, and neurodegenerative disorders.
The company is headquartered in Cambridge, Massachusetts, where it leases facility space on First Street. It conducts its operational and development activities within the United States, and all of its drug programs currently remain in the research or preclinical development stage.
Summary of the business section of Korro Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Korro Bio, Inc.
- Headquarters
- Cambridge, MA
- Address
- 60 First Street, 2nd Floor, Suite 250 02141
- Phone
- (617) 468-1999
- Employees
- 58, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- KRRO
- Exchange
- Nasdaq
- IPO date
- Oct 4, 2019
- Shares outstanding
- 15M, Aug 5, 2026
- Public float
- $88.97M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-130 reverse, Mar 26, 2024; 1-for-50 reverse, Nov 6, 2023
- SEC CIK
- 1703647
- CUSIP
- 500946108
- ISIN
- US5009461089
- EIN
- 47-2324450
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ram Aiyar | President and CEO, Director | 73,659 |
| Oliver Dolan | Senior Vice President, Finance | 16,241 |
| Todd Chappell | Chief Operating Officer | 24,464 |
| Jeffrey Cerio | General Counsel | 41,793 |
| Loic A. Vincent | Chief Scientific Officer | 25,797 |
| Olukemi Olugemo | Chief Medical Officer | – |
| Vineet Agarwal | Chief Financial Officer | 800 |
| Jean Francois Formela | Director | 132,650 |
| Katharine Knobil | Director | – |
| Timothy R. Pearson | Director | – |
| Ali Behbahani | Director | 1,297,893 |
| Nessan Bermingham | Director | 35,114 |
| Rachel Meyers | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David LLucchino | $0 | $0 | $1.80M | $4 | – |
| FY2025 Dr Aiyar | $3.12M | -$717.81K | $1.80M | $4 | – |
| FY2024 David LLucchino | $0 | $0 | $2.14M | $20 | – |
| FY2024 Dr Aiyar | $939.08K | -$179.93K | $2.14M | $20 | – |
| FY2023 David LLucchino | $3.88M | $1.80M | $1.52M | $25 | – |
| FY2023 Dr Aiyar | $2.86M | $8.47M | $1.52M | $25 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 58 full-time employees, including 44 who hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 6, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 6, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 6, 2023 | Name change | Name changed from Frequency Therapeutics, Inc. to Korro Bio, Inc. |
| Jul 27, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 29, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 4, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 23, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |